These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33250741)

  • 61. Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
    Soverini S; De Benedittis C; Mancini M; Martinelli G
    Oncologist; 2016 May; 21(5):626-33. PubMed ID: 27032870
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
    Preudhomme C; Révillion F; Merlat A; Hornez L; Roumier C; Duflos-Grardel N; Jouet JP; Cosson A; Peyrat JP; Fenaux P
    Leukemia; 1999 Jun; 13(6):957-64. PubMed ID: 10360386
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 65. De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China.
    Luo J; Du X; Lou J; Wu J; Ma L; Huang J; Wang L; Tu C; Liu Z; Chen L; Tan Y; Luo D; Liang H; Yin C; Cao R; Zhou X; Liu Q; Liu X; Xu N
    EJHaem; 2022 Nov; 3(4):1220-1230. PubMed ID: 36467815
    [No Abstract]   [Full Text] [Related]  

  • 66. Detection of
    Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
    Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
    Brown JT; Beldorth IJ; Laosinchai-Wolf W; Fahey ME; Jefferson KL; Ruskin AK; Roth JJ; Cai L; Watt CD; Press RD; Yang F; Hedges JB; Andruss BF
    J Mol Diagn; 2019 Jul; 21(4):718-733. PubMed ID: 31026597
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
    Amabile M; Giannini B; Testoni N; Montefusco V; Rosti G; Zardini C; Terragna C; Buonamici S; Ottaviani E; Soverini S; Fiacchini M; Bassi S; de Vivo A; Trabacchi E; Saglio G; Pane F; Baccarani M; Tura S; Martinelli G
    Haematologica; 2001 Mar; 86(3):252-9. PubMed ID: 11255271
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
    Gendron N; Belhouachi N; Morel V; Azgui Z; Maloum K; Nguyen-Khac F; Cayuela JM; Davi F; Merle-Béral H; Chapiro E
    Ann Biol Clin (Paris); 2014; 72(3):359-66. PubMed ID: 24876147
    [TBL] [Abstract][Full Text] [Related]  

  • 70. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia.
    Dasgupta S; Ray UK; Mitra AG; Bhattacharyya DM; Mukhopadhyay A; Das P; Gangopadhyay S; Roy S; Mukhopadhyay S
    Blood Res; 2017 Jun; 52(2):112-118. PubMed ID: 28698847
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    Pennisi MS; Stella S; Vitale SR; Puma A; Di Gregorio S; Romano C; Tirrò E; Massimino M; Antolino A; Siragusa S; Mannina D; Impera S; Musolino C; Mineo G; Martino B; Zammit V; Di Raimondo F; Manzella L; Stagno F; Vigneri P
    Front Oncol; 2019; 9():764. PubMed ID: 31456947
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Measuring fetal brain and lung transcripts in amniotic fluid supernatant: a comparison of digital PCR and RT-qPCR methods.
    Hui L; Beard S; Hannan NJ
    J Matern Fetal Neonatal Med; 2018 Dec; 31(23):3191-3196. PubMed ID: 28805106
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
    Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale.
    Furuya D; Moriai M; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
    Int J Clin Oncol; 2019 Jul; 24(7):871-875. PubMed ID: 30798394
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring.
    Langabeer SE; McCarron SL; Kelly J; Krawczyk J; McPherson S; Perera K; Murphy PT
    Case Rep Hematol; 2012; 2012():458716. PubMed ID: 22937329
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
    Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Influence of major
    Genthon A; Nicolini FE; Huguet F; Colin-Gil C; Berger M; Saugues S; Janel A; Hayette S; Cohny-Makhoul P; Cadoux N; Cayuela JM; Campos L; Guyotat D; Flandrin-Gresta P
    Oncotarget; 2020 Jun; 11(26):2560-2570. PubMed ID: 32655840
    [TBL] [Abstract][Full Text] [Related]  

  • 80. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.